Compare Amphastar Pharmaceuticals Inc (AMPH) vs Dover Corp (DOV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Dover Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Dover Corp trades at $215.41 (market cap $29.00B). The key difference: Dover Corp is far larger — about 35.1× Amphastar Pharmaceuticals Inc's market cap, and Dover Corp pays a 0.97% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | DOV | |
|---|---|---|
Market Cap | $826.08M | $29.00B |
Sector | Health | Industrials |
52-Week High | $30.81 | $233.31 |
52-Week Low | $16.87 | $161.16 |
Enterprise Value | $1.22B | $30.64B |
Dividend Yield | — | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Dover Corporation (DOV) trades at $215.33, up 1.78% today, with a bearish technical signal but strong fundamentals including a 13.3% net income margin and consistent earnings beats. Recent news highlights product launches in data center and industrial solutions, supporting revenue growth. The stock is supported by a high analyst buy consensus and a $251 price target, though technical indicators show resistance near $214.
Outlook is positive with robust profitability and analyst optimism, but risks include market volatility and execution challenges. The stock offers value through earnings growth and dividend yield, with upside potential if it breaks resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →
